Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00631_DB01097_nanopub.RA42cM2A2Uz7v7VSLvW_4mpPAOzH8pc7FwZj5L6BTL2-o#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00631_DB01097 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00631_DB01097 label "DDI between Clofarabine and Leflunomide - Immunosuppressants such as clofarabine may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy. [drugbank_resource:DB00631_DB01097]" assertion.
- drugbank_resource:DB00631_DB01097 identifier "drugbank_resource:DB00631_DB01097" assertion.
- drugbank_resource:DB00631_DB01097 title "DDI between Clofarabine and Leflunomide - Immunosuppressants such as clofarabine may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy." assertion.
- drugbank:DB01097 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00631_DB01097 assertion.
- drugbank:DB00631 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00631_DB01097 assertion.